Drug Trial Radar · NCT03994731
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Jun 13, 2019
Primary completion
Mar 17, 2021
Study completion Apr 11, 2022
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.
Conditions
- Gout
Interventions
PegloticaseBiological
IV pegloticase 8 mg Q2W
methotrexateDrug
Oral MTX 15 mg weekly
placeboDrug
Oral placebo for MTX
folic acidDietary supplement
Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
gout flare prophylaxis regimenDrug
Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
fexofenadineDrug
For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
acetaminophenDrug
For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
methylprednisoloneDrug
For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Time frame: Month 6 (Weeks 20, 21, 22, 23 and 24)
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Orthopedic Physicians Alaska
Anchorage, Alaska
Arizona Arthritis and Rheumatology Research, PLLC - Flagstaff
Flagstaff, Arizona
Arizona Arthritis and Rheumatology Research, PLLC-West
Glendale, Arizona
Arizona Arthritis and Rheumatology Research, PLLC-East
Mesa, Arizona
Applied Research Center of Arkansas, Inc
Little Rock, Arkansas
TriWest Research Associates
El Cajon, California
Advanced Investigative Medicine, Inc.
Hawthorne, California
Axis Clinical Trials
Los Angeles, California
ACRC Studies
Poway, California
ClinEdge Sierra Rheumatology, Inc.
Roseville, California
East Bay Rheumatology Medical Group, Inc.
San Leandro, California
Providence St. John's Health Clinic
Santa Monica, California
Medvin Clinical Research
Tujunga, California
San Fernando Valley Health Institute
Van Nuys, California
Ventura Clinical Trials
Ventura, California
University of Colorado Division of Rheumatology
Aurora, Colorado
Denver Arthritis Clinic
Denver, Colorado
Avail Clinical Research
DeLand, Florida
Prohealth Research Center
Doral, Florida
Omega Research Maitland
Orlando, Florida
DMI Research
Pinellas Park, Florida
Napa Research Center
Pompano Beach, Florida
GCP Clinical Research
Tampa, Florida
Florida Medical Clinic, LLC
Zephyrhills, Florida
St. Luke's Clinic - Rheumatology
Meridian, Idaho
MD Medical Research
Oxon Hill, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland
Infusion Associates
Grand Rapids, Michigan
Clinical Research Institute of Michigan, LLC
Saint Clair Shores, Michigan
Benefis Hospital
Great Falls, Montana
Physician Research Collaboration, LLC
Lincoln, Nebraska
Santa Fe Rheumatology
Santa Fe, New Mexico
Long Island Arthritis & Osteoporosis Care
Babylon, New York
Buffalo Rheumatology and Medicine
Orchard Park, New York
NorthEast Rheumatology/Atrium Health
Concord, North Carolina
NorthEast Rheumatology
Concord, North Carolina
Medication Management, LLC
Greensboro, North Carolina
ClinEdge PMG Research of Hickory, LLC
Hickory, North Carolina
ClinEdge PMG Research of Salisbury, LLC
Salisbury, North Carolina
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.